UF Health Cancer Center Oncology Grand Rounds
Presents

“Promising New Approaches for Relapsed/Refractory Non-Hodgkin Lymphoma”

Nancy L. Bartlett, MD
Koman Chair in Medical Oncology and Professor of Medicine
Siteman Cancer Center
Washington University School of Medicine

Wednesday, September 18, 2019
12:00 – 1:00 pm
Communique C1-004

Videostreaming:  https://mediasite.video.ufl.edu/Mediasite/Play/21edd17561a5465e8cc7640db06735561d

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

1. Explain the purported mechanisms of action for novel agents in NHL such as CAR-T cells, bispecific antibodies, antibody drug conjugates, and novel monoclonal antibodies.
2. Estimate the response rates for patients with relapsed and refractory NHL treated with novel targeted agents.
3. Describe the common toxicities of the novel agents for relapsed/refractory NHL.

Speaker Disclosure:
Dr. Nancy Bartlett has disclosed that she has grant/research support with ADC Therapeutics, Affimed, Autolus, Bristol-Myers Squibb, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Kite Pharma, Merck, Millennium, Pfizer, Pharmacyclics, and Seattle Genetics; and other financial or material support from BTG Advisory Board, Acerta Advisory Board, and ADC Therapeutics Advisory Board. No one else in a position to control content has any financial relationship(s) to disclose.

Accreditation: The University of Florida, College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Section # 0257, 0258